Download Now: Product Catalog

Curapath is a European Contract Development and Manufacturing Organization (CDMO) specialized in lipid- and polymer-based delivery systems. We support biotech and pharmaceutical companies from early development through GMP-ready manufacturing.

Our core expertise includes polymer and lipid excipients, lipid nanoparticles (LNPs), polymer nanoparticles (PNPs), polymer–drug conjugates, and coating polymers.

The catalog includes polymer- and lipid-based excipients for non-viral drug delivery, including transfection reagents, PEG alternatives,shielding lipids for LNPs, solubilizing polymers, polymer–drug conjugate backbones, and polycationic polymers for medical device applications.

These materials support RNA, DNA, proteins, peptides, and small molecules across vaccines, gene therapy, gene editing, oncology, and biologics formulation.

Materials are available across different quality grades,depending on the product and development stage: 

• Research-grade materials for early feasibility studies

• GMP-compatible or GMP-grade materials for clinical andcommercial programs

Availability of GMP grade depends on the specific polymer orlipid and can be discussed on a case-by-case basis.

Yes. Wherever possible, materials are designed and manufactured with scalability and reproducibility in mind.
Our development approach prioritizes:

• Transferability between scales
• Batch-to-batch consistency
• Alignment with regulatory expectations

This supports a smoother transition from early development to clinical manufacturing.

Yes. Our PEG alternatives are specifically designed to overcomeknown PEG limitations, including:

• Reduced immunogenicity
• Avoidance of anti-PEG antibody formation
• Lower bioaccumulation
• Improved potential for repeat administration

Suitability depends on the application and formulation context.

Yes. In addition to off-the-shelf catalog materials, weoffer custom synthesis and bespoke polymer development services.

This includes:

• Design of new polymer architectures
• Adaptation of existing platforms to specific needs
• Custom functionalization or conjugation strategies
• Scale-up and transfer to GMP manufacturing when required

Custom projects are developed in close collaboration to ensure technical feasibility and regulatory alignment.

For custom synthesis projects please contact-us

Yes, several platforms in our catalog are designed to support targeted delivery strategies across a range of therapeutic modalities, including nanoparticles engineered for extrahepatic and cell-specific delivery. These strategies include both passive and active targeting mechanisms that can be tailored to your program goals.

We have recently integrated the CliCr® bioconjugation technology into our portfolio via a co-exclusive agreement with Cristal Therapeutics. CliCr® is a site-specific, stable, and scalable bioconjugation platform that enables precise attachment of biomolecules to polymeric and lipid nanoparticles (LNPs),  greatly enhancing targeting capabilities to difficult-to-reach sites such as pulmonary tissue, brain, and T cells for in-vivo applications. This expansion of our targeting arsenal strengthens our ability to design next-generation targeted drug delivery systems for nucleic acids and other biologics.

Targeting strategies and platform suitability depend on the therapeutic modality and biological context of your program.

You can contact us directly through the catalog inquiry form to:

• Request samples
• Discuss quantities and grades
• Explore custom synthesis options
• Initiate technical or regulatory discussions

Each request is reviewed to ensure the most suitablesolution is proposed.

Also you can find different formats of our products in our distributors pages:

• Nacalai Tasque
• Cayman Chemicals
• Iris Biotech